Spectral Medical (Edtxf) (TSE:EDT) has released an update.
Spectral Medical has hit a milestone in its Tigris trial, enrolling 105 patients by the end of April 2024, marking a record month for patient enrollment in the study for septic shock treatment. The late-stage theranostic company is nearing completion of the trial with only 45 more participants needed. Spectral’s PMX device, aimed at treating septic shock by removing endotoxin from the bloodstream, has been used in over 340,000 patients worldwide and is currently under review for FDA approval in the US.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.
